Bicycle Therapeutics plc Operating Lease Cost
Bicycle Therapeutics plc (BCYC) reported Operating Lease Cost of $820.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-07-30
- Bicycle Therapeutics plc operating lease, cost for the quarter ending 2026-06-30 was $820.00K, a 36.24% decline year-over-year.
- Bicycle Therapeutics plc operating lease, cost for the quarter ending 2026-03-31 was $1.35M, a 8.07% increase year-over-year.
- Bicycle Therapeutics plc operating lease, cost for the quarter ending 2025-12-31 was $1.28M, a 0.87% increase year-over-year.
- Bicycle Therapeutics plc operating lease, cost for the quarter ending 2025-09-30 was $1.29M, a 5.02% decline year-over-year.
- Bicycle Therapeutics plc operating lease, cost for fiscal 2025 was $5.10M, a 3.76% decline from fiscal 2024.
- Bicycle Therapeutics plc operating lease, cost for fiscal 2024 was $5.30M, a 2.02% decline from fiscal 2023.
- Bicycle Therapeutics plc operating lease, cost for fiscal 2023 was $5.41M, a 42.69% increase from fiscal 2022.
- Bicycle Therapeutics plc operating lease, cost for fiscal 2022 was $3.79M, a 209.64% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $820.00K 10-Q · filed 2026-07-30 | $2.17M 10-Q · filed 2026-07-30 | $3.45M derived: sum of 3 quarters · filed 2026-07-30 | $4.74M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.35M 10-Q · filed 2026-04-30 | $2.63M derived: sum of 2 quarters · filed 2026-04-30 | $3.92M derived: sum of 3 quarters · filed 2026-04-30 | $5.20M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.56M derived: sum of 2 quarters · filed 2026-03-17 | $3.85M derived: sum of 3 quarters · filed 2026-07-30 | $5.10M 10-K · filed 2026-03-17 |
| 2025-09-30 | $1.29M 10-Q · filed 2025-10-30 | $2.57M derived: sum of 2 quarters · filed 2026-07-30 | $3.82M 10-Q · filed 2025-10-30 | $5.09M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.29M 10-Q · filed 2026-07-30 | $2.54M 10-Q · filed 2026-07-30 | $3.80M derived: sum of 3 quarters · filed 2026-07-30 | $5.16M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $1.25M 10-Q · filed 2026-04-30 | $2.52M derived: sum of 2 quarters · filed 2026-04-30 | $3.87M derived: sum of 3 quarters · filed 2026-04-30 | $5.21M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.62M derived: sum of 2 quarters · filed 2026-03-17 | $3.96M derived: sum of 3 quarters · filed 2026-03-17 | $5.30M 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.35M 10-Q · filed 2025-10-30 | $2.69M derived: sum of 2 quarters · filed 2025-10-30 | $4.03M 10-Q · filed 2025-10-30 | $5.38M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $1.34M 10-Q · filed 2025-08-08 | $2.68M 10-Q · filed 2025-08-08 | $4.03M derived: sum of 3 quarters · filed 2026-03-17 | $5.39M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $1.34M 10-Q · filed 2025-05-01 | $2.69M derived: sum of 2 quarters · filed 2026-03-17 | $4.06M derived: sum of 3 quarters · filed 2026-03-17 | $5.42M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.71M derived: sum of 2 quarters · filed 2026-03-17 | $4.08M derived: sum of 3 quarters · filed 2026-03-17 | $5.41M 10-K · filed 2026-03-17 |
| 2023-09-30 | $1.36M 10-Q · filed 2024-10-31 | $2.73M derived: sum of 2 quarters · filed 2024-10-31 | $4.06M 10-Q · filed 2024-10-31 | $4.98M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $1.37M 10-Q · filed 2024-08-06 | $2.69M 10-Q · filed 2024-08-06 | $3.62M derived: sum of 3 quarters · filed 2025-02-25 | $4.54M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $1.33M 10-Q · filed 2024-05-02 | $2.25M derived: sum of 2 quarters · filed 2025-02-25 | $3.17M derived: sum of 3 quarters · filed 2025-02-25 | $4.21M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $924.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.85M derived: sum of 2 quarters · filed 2025-02-25 | $2.88M derived: sum of 3 quarters · filed 2025-02-25 | $3.79M 10-K · filed 2025-02-25 |
| 2022-09-30 | $924.00K 10-Q · filed 2023-11-02 | $1.96M derived: sum of 2 quarters · filed 2023-11-02 | $2.87M 10-Q · filed 2023-11-02 | $3.32M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $1.04M 10-Q · filed 2023-08-03 | $1.94M 10-Q · filed 2023-08-03 | $2.39M derived: sum of 3 quarters · filed 2024-02-20 | $2.67M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $906.00K 10-Q · filed 2023-05-04 | $1.36M derived: sum of 2 quarters · filed 2024-02-20 | $1.63M derived: sum of 3 quarters · filed 2024-02-20 | $1.90M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $451.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $724.00K derived: sum of 2 quarters · filed 2024-02-20 | $997.00K derived: sum of 3 quarters · filed 2024-02-20 | $1.22M 10-K · filed 2024-02-20 |
| 2021-09-30 | $273.00K 10-Q · filed 2022-11-03 | $546.00K derived: sum of 2 quarters · filed 2022-11-03 | $773.00K 10-Q · filed 2022-11-03 | $1.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $273.00K 10-Q · filed 2022-08-04 | $505.00K 10-Q · filed 2022-08-04 | $732.00K derived: sum of 3 quarters · filed 2023-02-28 | $958.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $232.00K 10-Q · filed 2022-05-05 | $459.00K derived: sum of 2 quarters · filed 2023-02-28 | $685.00K derived: sum of 3 quarters · filed 2023-02-28 | $905.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $453.00K derived: sum of 2 quarters · filed 2023-02-28 | $673.00K derived: sum of 3 quarters · filed 2023-02-28 | $896.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $226.00K 10-Q · filed 2021-11-04 | $446.00K derived: sum of 2 quarters · filed 2021-11-04 | $669.00K 10-Q · filed 2021-11-04 | $900.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $220.00K 10-Q · filed 2021-08-05 | $443.00K 10-Q · filed 2021-08-05 | $674.00K derived: sum of 3 quarters · filed 2022-03-01 | $893.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $223.00K 10-Q · filed 2021-05-06 | $454.00K derived: sum of 2 quarters · filed 2022-03-01 | $673.00K derived: sum of 3 quarters · filed 2022-03-01 | $897.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $450.00K derived: sum of 2 quarters · filed 2022-03-01 | $674.00K derived: sum of 3 quarters · filed 2022-03-01 | $900.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $219.00K 10-Q · filed 2019-11-07 | $443.00K derived: sum of 2 quarters · filed 2019-11-07 | $669.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $224.00K 10-Q · filed 2019-08-08 | $449.00K 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |